15 terminated. 15 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 5 | Terminated 5 |
| Phase 3 | 1 | Terminated 1 |
Follow Recurrent Grade 2 Follicular Lymphoma: new trials by email Literature Review of Recurrent Grade 2 Follicular Lymphoma trials Research Report on Recurrent Grade 2 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma alisertib, rituximab, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 14 | 2013-05-21 | 2018-06-06 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma Ofatumumab, Bortezomib - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2011-10-01 | 2014-07-30 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma alvocidib - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2005-12-01 | 2016-08-08 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | Medical College of Wisconsin | 30 | 2004-08-01 | 2023-01-05 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma ipilimumab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2004-06-01 | 2014-05-30 |
| FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma romidepsin, rituximab, fludarabine phosphate - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 60 | 2004-01-01 | 2013-07-01 |
| Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma recombinant interferon alfa, thalidomide, laboratory biomarker analysis - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 35 | 2001-07-01 | 2013-01-25 |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 81 | 2001-04-01 | 2018-08-09 |
| 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma nelarabine - Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Terminated | National Cancer Institute (NCI) | 111 | 2000-04-01 | 2013-01-23 |
Lymphoma, Follicular (15) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Mantle-Cell (10) · Lymphoma, Large B-Cell, Diffuse (9) · Waldenstrom Macroglobulinemia (9) · Burkitt Lymphoma (7) · Lymphoma, Non-Hodgkin (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Hodgkin Disease (5) · Lymphoma, Large-Cell, Immunoblastic (5) · Lymphoma, T-Cell, Cutaneous (5) · Mycosis Fungoides (5) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Sezary Syndrome (5)
Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoma (15) · Lymphoproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Hematologic Diseases (12) · Chronic Disease (11) · Disease Attributes (11) · Leukemia (11) · Leukemia, B-Cell (11) · Leukemia, Lymphoid (11) · Pathologic Processes (11)
Rituximab (9) · fludarabine phosphate (3) · Cyclophosphamide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Tacrolimus (2) · Antilymphocyte Serum (1) · Bortezomib (1) · Brentuximab Vedotin (1) · Busulfan (1) · CT-P10 (1) · CTLA-4 Antigen (1) · Carmustine (1) · Deferasirox (1) · Drug Therapy (1)
National Cancer Institute (NCI) (7) · Academic and Community Cancer Research United (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Medical College of Wisconsin (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · University of Nebraska (1)
United States (15)
Adam Petrich, MD (1) · Ajay Gopal (1) · Andre Goy (1) · Ashraf Badros (1) · Catherine S Diefenbach (1) · Craig Okada (1) · Jeffrey Jones (1) · John Sweetenham (1) · Kristie Blum, MD (1) · Mary Horowitz, MD (1) · Mohamed Sorror (1) · Robert Bociek, MD (1) · Stephen Ansell (1) · Thomas Witzig (1) · Vinod Pullarkat, MD (1)
P30CA015083 (2), N01CM00070 (1), N01CM17003 (1), P30CA015704 (1), P30CA016058 (1), P30CA036727 (1), R21CA119519 (1), U01CA069854 (1), U01CA069912 (1), U01CA076576 (1), U01HL069294 (1), U24CA076518 (1)